Sensus Healthcare Q4 revenue misses analyst expectations

Sensus Healthcare

12/02/2026 21:20

Overview

Medical device company's Q4 revenue missed analyst expectations

Net loss for Q4 was $3.2 mln

Company shipped 14 SRT systems in Q4, up from six in Q3

Outlook

Sensus Healthcare expects sequential-quarter revenue growth in Q1 2026

Company aims for full-year profitability in 2026

Result Drivers

INCREASED SRT SHIPMENTS - Shipped 14 SRT systems in Q4, up from six in Q3, driven by international demand and new reimbursement codes

FDA PROGRAM EXPANSION - Significant increase in FDA treatments delivered, with 11,411 treatments in 2025 compared to 1,367 in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$4.94 mln
$8.35 mln (3 Analysts)
Q4 Net Income
-$3.17 mln
Q4 Adjusted EBITDA
Miss
-$2.97 mln
-$1.60 mln (1 Analyst)
Q4 Basic EPS
-$0.19
Q4 Operating Expenses
$5.05 mln
Q4 Pretax Profit
-$2.99 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Sensus Healthcare Inc is $8.00, about 68.1% above its February 11 closing price of $4.76

Press Release: ID:nBw2nMQqja

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)